Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 901–1,000 of 1,002
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice
Hou, J., Xie, S., Gao, J., Jiang, T., Zhu, E., Yang, X., Jin, Z., Long, H., Zhang, A., Yang, F., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00511-9 · Cited by 24
Nunno, V. D., Mollica, V., Schiavina, R., Nobili, E., Fiorentino, M., Brunocilla, E., Ardizzoni, A., & Massari, F. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.08.007 · Cited by 22
Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22
Savard, M.-F., Wells, J. C., Graham, J., Dudani, S., Steinharter, J. A., McGregor, B. A., Donskov, F. N., Bjarnason, G. A., Vaishampayan, U. N., Hansen, A. R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0605 · Cited by 22
Monteiro, F. S. M., Soares, A., Debiasi, M., Schutz, F. A. B., Maluf, F. C., Bastos, D. A., Sasse, A. D., Cauduro, C. G. D. S., Mendes, G. O., Ziegelmann, P. K., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.02.012 · Cited by 22
Ueda, K., Ogasawara, N., Yonekura, S., Matsunaga, Y., Hoshino, R., Kurose, H., Chikui, K., Uemura, K., Nakiri, M., Nishihara, K., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14127 · Cited by 22
Chakraborty, A. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.012 · Cited by 25
Immune Checkpoint Inhibitors in Genitourinary Malignancies
Thana, M., & Wood, L. A. (2020) · Current Oncology · doi:10.3747/co.27.5121 · Cited by 23
Eichenauer, T., Simmendinger, L., Fraune, C., Mandelkow, T., Blessin, N. C., Kluth, M., Hube‐Magg, C., Möller, K., Clauditz, T. S., Weidemann, S. A., et al. (2020) · World Journal of Urology · doi:10.1007/s00345-020-03200-4 · Cited by 26
Hänze, J., Wegner, M., Noeßner, E., Hofmann, R. W., & Hegele, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00728-8 · Cited by 29
Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma
Westerman, M. E., Shapiro, D. D., Wood, C. G., & Karam, J. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.010 · Cited by 24
Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma
Yao, J., Chen, X., Xi, W., Zhu, Y., Wang, H., Hu, X., & Guo, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01181 · Cited by 22
“Immunotherapy with immune checkpoint inhibitors (monoclonal antibodies) of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PDL1) has also shown a good effect in recent trials, particularly in high-risk mRCC (6).”
BackgroundMroue, A., Moujaess, E., Kourié, H. R., Azar, H., Finianos, S., & Chelala, D. N. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103169 · Cited by 22
van Asten, S. D., de Groot, R., van Loenen, M. M., Castenmiller, S. M., de Jong, J., Monkhorst, K., Haanen, J. B. A. G., Amsen, D., Bex, A., Spaapen, R. M., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860482 · Cited by 22
“Antibodies directed against PD-1 or its ligands PD-L1 and PD-L2 in combination with anti-CTLA-4 or axitinib, a VEGFR tyrosine kinase inhibitor, resulted in 50% objective response rates of metastatic clear-cell RCC patients, and led to complete responses in 10% of the patients.(13,14) This combination therapy has there…”
BackgroundThe Immunotherapy Landscape in Adrenocortical Cancer
Pegna, G. J., Roper, N., Kaplan, R. N., Bergsland, E. K., Kiseljak‐Vassiliades, K., Habra, M. A., Pommier, Y. G., & Rivero, J. D. (2021) · Cancers · doi:10.3390/cancers13112660 · Cited by 35
“Targeted agents against the vascular endothelial growth factor (VEGF) pathway have been particularly promising in combination with immune checkpoint inhibitor therapies, including axitinib with pembrolizumab for metastatic RCC and bevacizumab with atezolizumab in unresectable hepatocellular carcinoma (HCC) [74,75].”
BackgroundGeynisman, D. M., Maranchie, J. K., Ball, M. W., Bratslavsky, G., & Singer, E. A. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.04.038 · Cited by 25
“The third breakthrough came in the form of combining tyrosine kinase with checkpoint inhibitors in the frontline setting as axitinib with pembrolizumab [137] or avelumab [138] was approved in 2019, followed by cabozantinib with nivolumab [139] and lenvatinib with pembrolizumab [140] in 2021.”
BackgroundChoueiri, T. K., Albiges, L. K., Atkins, M. B., Bakouny, Z., Bratslavsky, G., Braun, D. A., Haas, N. B., Haanen, J. B. A. G., Hakimi, A. A., Jewett, M. A. S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3238 · Cited by 22
Self-citationWu, X., Jiang, D., Liu, H., Lu, X., Lv, D., & Li, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745945 · Cited by 28
Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature
Bimbatti, D., Maruzzo, M., Pierantoni, F., Diminutto, A., Dionese, M., Deppieri, F. M., Lai, E., Zagonel, V., & Basso, U. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103579 · Cited by 23
Kim, I.-H., & Lee, H. J. (2022) · Biomedicines · doi:10.3390/biomedicines10020251 · Cited by 23
“PD-L1 positivity was defined as CPS 1 or higher, and approximately 30% of patients were positive.”
MethodInfluentialMori, K., Quhal, F., Yanagisawa, T., Katayama, S., Pradère, B., Laukhtina, E., Rajwa, P., Mostafaei, H., Motlagh, R. S., Kimura, T., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108720 · Cited by 23
Colafella, K. M. M., van Dorst, D. C. H., Neuman, R. I., van Doorn, L., Neves, K. B., Montezano, A. C. I., Garrelds, I. M., van Veghel, R., VRIES, R. D., Uijl, E., et al. (2022) · Clinical Science · doi:10.1042/cs20220182 · Cited by 25
Kidney cancer: From tumor biology to innovative therapeutics
Rinaldi, L., Senatore, E., Feliciello, S., Chiuso, F., Insabato, L., & Feliciello, A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189240 · Cited by 28
Wen, H., Shi, Z., Zhu, X., Wang, L., & Chen, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643533 · Cited by 26
Toward a genome-based treatment landscape for renal cell carcinoma
Massari, F., Nunno, V. D., Santoni, M., Gatto, L., Caserta, C., Morelli, F., Zafarana, E., Carrozza, F., Mosca, A., Mollica, V., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.020 · Cited by 21
A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer
Korentzelos, D. K., Clark, A. M., & Wells, A. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197304 · Cited by 21
Yang, N., Liu, Z., Pang, S., Wu, J., Liang, J., & Sun, L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.124 · Cited by 21
Moik, F., Makatsariya, A. D., & Ay, C. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.016 · Cited by 21
Matsuki, M., Hirohashi, Y., Nakatsugawa, M., Murai, A., Kubo, T., Hashimoto, S., Tokita, S., Murata, K., Kanaseki, T., Tsukahara, T., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03048-6 · Cited by 23
Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
Aurilio, G., Santoni, M., Massari, F., Cimadamore, A., Rizzo, A., Mollica, V., Verri, E., Battelli, N., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13205229 · Cited by 21
Novel emerging biomarkers to immunotherapy in kidney cancer
Ged, Y. M. A., & Voss, M. H. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059367 · Cited by 22
Kato, T., Fujita, K., Minami, T., Nagahara, A., Hyashi, Y., Nakata, W., Matsuzaki, K., Nakano, K., Hatano, K., Kawashima, A., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02215-8 · Cited by 24
Raschi, E., Fusaroli, M., Giunchi, V., Repaci, A., Pelusi, C., Mollica, V., Massari, F., Ardizzoni, A., Poluzzi, E., Pagotto, U., et al. (2022) · Cancers · doi:10.3390/cancers14194610 · Cited by 23
“2% for sunitinib) [34], and a CLEAR trial for lenvatinib plus pembrolizumab (1.”
BackgroundHarari, O., Soltanifar, M., Cappelleri, J. C., Verhoek, A., Ouwens, M., Daly, C., & Heeg, B. M. S. (2022) · Research Synthesis Methods · doi:10.1002/jrsm.1608 · Cited by 21
Thouvenin, J., Masson, C., Boudier, P., Maillet, D., Kuchler‐Bopp, S., Barthélémy, P., & Massfelder, T. (2023) · Cancers · doi:10.3390/cancers15030793 · Cited by 22
“These PD1-based combinations include pembrolizumab (anti-PD1 monoclonal antibody) + axitinib (anti-VEGFR TKI), which was evaluated in the KEYNOTE 426 trial [7], nivolumab + cabozantinib (anti-VEGFR, c-MET, AXL, c-KIT, and RET TKI), which was evaluated in the Checkmate9ER trial [8], and, finally, pembrolizumab + lenvat…”
InfluentialThe role of immunotherapy in non-clear cell renal cell carcinoma
Climent, C., Soriano, S., Bonfill, T., López, N. V., Rodríguez-Castells, M., Sierra, M., Cobo, P. A., Gil, M. F., Busquets, M., Carrasco, A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.941835 · Cited by 24
“These studies were Checkmate-9ER (cabozantinib + nivolumab), Keynote426 (axitinib + pembrolizumab), and CLEAR (lenvatinib + pembrolizumab) (21, 22, 26), all focusing on ccRCC and not including less frequent subtypes of renal cancer.”
MethodLee, D., Gittleman, H. R., Weinstock, C., Suzman, D. L., Bloomquist, E. W., Agrawal, S., Brave, M. H., Brewer, J. L., Fallah, J., Singh, H., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.05.030 · Cited by 21
Jang, A., Lanka, S. M., Jaeger, E., Lieberman, A., Huang, M., Sartor, O. A., Mendiratta, P., Brown, J. R., Garcia, J. A., Farmer, T. E., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00131 · Cited by 24
Liu, X.-D., Zhang, Y.-T. Y., McGrail, D. J., Zhang, X., Lam, T., Hoang, A. G., Hasanov, E., Manyam, G. C., Peterson, C. B., Zhu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1003 · Cited by 23
Coschi, C. H., & Juergens, R. A. (2023) · Current Oncology · doi:10.3390/curroncol31010001 · Cited by 26
Ziogas, D. C., Theocharopoulos, C., Aravantinou-Fatorou, K., Boukouris, A. E., Stefanou, D. T., Anastasopoulou, A. N., Lialios, P., Lyrarakis, G., & Gogas, H. J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104635 · Cited by 23
Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma
Shao, Y., Xiong, S.-C., Sun, G., Dou, W.-C., Hu, X., Yang, W., Lia, T., Deng, S., Wei, Q., Zeng, H., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2775 · Cited by 21
New Treatments in Renal Cancer: The AhR Ligands
Itkin, B., Breen, A. F., Turyanska, L., Sandes, E. O., Bradshaw, T. D., & Loaiza‐Perez, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103551 · Cited by 22
Rausch, M., Weiss, A., Achkhanian, J., Rotari, A., & Nowak-Sliwinska, P. M. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0890-y · Cited by 23
Elaidi, R., Phan, L., Borchiellini, D., Barthélémy, P., Ravaud, A., Oudard, S. M., & Vano, Y. A. (2020) · Cancers · doi:10.3390/cancers12061673 · Cited by 21
“Of these, three published phase 3 randomized clinical trials matched our selection criteria (2843 patients, Figure 1): CheckMate 209–214 [4], Keynote 426 [8], and Javelin Renal 101 [9].”
Self-citationLiu, T., Jin, B., Chen, J., Wang, H., Lin, S., Dang, J., & Li, G. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920940927 · Cited by 23
Bensimon, A. G., Zhong, Y., Swami, U., Briggs, A., Young, J., Feng, Y., Song, Y., Signorovitch, J., Adejoro, O. O., Chakravarty, A., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1799771 · Cited by 25
Self-citationCarril-Ajuria, L., Lora, D., Carretero-González, A., Martín-Soberón, M., Rioja, P., Castellano, D., & de Velasco, G. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.10.004 · Cited by 22
Khan, Y., Slattery, T. D., & Pickering, L. M. (2020) · Cancers · doi:10.3390/cancers12123750 · Cited by 22
“KEYNOTE 426 [33] Prospective, randomized phase III (sub-group analysis) RCC with sarcomatoid differentiation Pembrolizumab + Axitinib vs.”
BackgroundTumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
Steindl, A., Alpár, D., Heller, G., Mair, M. J., Gatterbauer, B., Dieckmann, K. U., Widhalm, G., Hainfellner, J. A., Schmidinger, M., Bock, C., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100057 · Cited by 21
“496 Median density of CD3þ TIL (range) extracranial 454 (70-5192) In RCC specimen 453 (71-5192) In lung metastasis specimen 616 (70-1206) Median density of CD45ROþ TIL (range) intracranial 47 (1-2052) 0.”
BackgroundInfluentialHah, Y. S., & Koo, K. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094452 · Cited by 26
“A total of 861 patients with chemotherapy-naïve, advanced RCC were randomly allocated at a 1:1 ratio to rec ive pe rolizumab (200 mg) every three we ks with axitinib (5 mg) twice daily or sunitinib (50 mg) daily for four weeks (6-week cycle) [78].”
MethodInfluentialFujiwara, Y., Horita, N., Namkoong, H., & Galsky, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.012 · Cited by 23
Dumond, A., Montemagno, C., Vial, V., Grépin, R., & Pagès, G. (2021) · Cells · doi:10.3390/cells10051222 · Cited by 21
“Currently, the standard of care for RCC is a combination of anti-PD1 (pembrolizumab) plus axitinib [22] or a combination of an anti-PD1 (nivolumab) plus an anti-CTLA4 (ipilimumab) [29], since lymphatic vessels represent one of the main routes of metastatic spreading.”
BackgroundDing, L., Dong, H., Zhou, T. R., Wang, Y. H., Yan, T., Li, J. C., Wang, Z. Y., Liang, C., & Liang, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4190 · Cited by 25
Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
Digiacomo, G., Volta, F., Garajová, I., Balsano, R., & Cavazzoni, A. (2021) · Life · doi:10.3390/life11080843 · Cited by 22
Immunotherapy for prostate cancer: Requirements for a successful regime transfer
Jeong, S., & Kwak, C. H. (2022) · Korean journal of urology · doi:10.4111/icu.20210369 · Cited by 21
“Other phase-3 trials, including KEYNOTE-426, JAVELIN Renal 101, and IMmotion161, demonstrated the benefits of anti-PD-1 or PD-L1 agents in combination with axitinib or bevacizumab, with superior OS and progression-free survival to sunitinib [13,14].”
ResultŠtudentová, H., Volakova, J., Spisarová, M., Zemánková, A., Aiglová, K., Szotkowski, T., & Melichar, B. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02121-3 · Cited by 22
Self-citationAntibody-drug conjugates: beyond current approvals and potential future strategies
Menon, S., Parakh, S., Scott, A. M., & Gan, H. K. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00082 · Cited by 22
Progress on angiogenic and antiangiogenic agents in the tumor microenvironment
Xu, J., & Tang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1491099 · Cited by 21
“In an open-label phase 3 trial (KEYNOTE-426), Pembrolizumab combined with Axitinib signi fi cantly extended overall survival and progression-free survival, while also increasing objective response rates in previously untreated patients with advanced renal cell carcinoma (163).”
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
Gust, K. M., Rebhan, K., Resch, I., Shariat, S. F., & Necchi, A. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000783 · Cited by 20
“In metastatic renal cell cancer, combinations of ipilimumab/nivolumab [60], avelumab/axitinib [61], and pembrolizumab/axitinib [62] have recently been approved by the FDA and the EMA, though these combination therapies might also result in increased toxicity, and therefore the clinical benefit has to be weighed agains…”
BackgroundGuénolé, M., Lucia, F., Bourbonne, V., Dissaux, G., Reygagne, E., Goasduff, G., Pradier, O., & Schick, U. (2020) · BMC Cancer · doi:10.1186/s12885-020-07491-z · Cited by 21
Guida, A., Teuff, G. L., Alves, C., Colomba, É., Nunno, V. D., Derosa, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Oncotarget · doi:10.18632/oncotarget.27762 · Cited by 21
“The CPI based regimen has transformed the firstline treatment approach in mRCC management, with two possible distinct approved approaches: doublet of CPI in intermediate and poor IMDC risk patients or VEGF/ TKI plus CPI in mRCC patients regardless of IMDC risk group [4, 12, 13].”
MethodDragomir, A., Nazha, S., Tanguay, S., Breau, R. H., Bhindi, B., Rendon, R., Kapoor, A., Hotte, S. J., Basappa, N. S., Fairey, A., et al. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.10.004 · Cited by 20
Self-citationNemoto, Y., Ishihara, H., Nakamura, K., Tachibana, H., Fukuda, H., Yoshida, K., Kobayashi, H., Iizuka, J., Shimmura, H., Hashimoto, Y., et al. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-03042-y · Cited by 20
Dong, S., Yang, H., Tang, Z., Ke, Y., Wang, H., Li, W., & Tian, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731905 · Cited by 20
“As a result, targeted therapies represented by VEGF inhibitors (bevacizumab, sunitinib, axitinib), as first-line treatment for advance patients, have been developed, showing impressive clinical outcome (4, 47, 48).”
BackgroundLiu, J., Chen, C., Geng, R., Shao, F., Yang, S., Zhong, Z., Ni, S., & Bai, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.037 · Cited by 21
“Immune checkpoint inhibitors (ICIs), have shown superiority of treatment effect over conventional therapies in many tumors, particularly in lung cancer, melanoma and kidney cancer, which dramatically improv overall survival for patients [8,9].”
BackgroundStellato, M., Buti, S., Maruzzo, M., Bersanelli, M., Pierantoni, F., Giorgi, U. D., Napoli, M. D., Iacovelli, R., Vitale, M. G., Ermacora, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021096 · Cited by 20
“Real-world physician-assessed progression and response were based on radiographic criteria using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines [21], with imaging assessments occurring about every three months.”
MethodCatalano, M., Procopio, G., Sepe, P., Santoni, M., Sessa, F., Villari, D., Nesi, G., & Roviello, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108499 · Cited by 21
Immunotherapy in the Treatment of Localized Genitourinary Cancers
Necchi, A., Faltas, B. M., Slovin, S. F., Meeks, J. J., Pal, S. K., Schwartz, L. H., Huang, R. S. P., Li, R., Manley, B. J., Chahoud, J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2174 · Cited by 20
Chen, X., Xu, Z., Wu, C., Xie, L., Wang, P., & Liu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1255577 · Cited by 23
Xu, Y., Hua, J., Que, H., Zeng, T., Li, Q., Deng, J., & Xie, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12067-2 · Cited by 20
Fazio, N., Cella, C. A., Re, M. D., Laffi, A., Rubino, M., Zagami, P., & Spada, F. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1700951 · Cited by 20
Fiala, O., Fínek, J., Poprach, A., Melichar, B., Kopecký, J., Zemanová, M., Kopečková, K., Mlcoch, T., Doležal, T., Čápková, L., et al. (2020) · Cancers · doi:10.3390/cancers12040808 · Cited by 20
Self-citationLin, Z., Chen, B., Hung, Y., Huang, P.-H., Shen, Y., Shao, Y., Hsu, C., Cheng, A., Lee, R., Chao, Y., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0143 · Cited by 20
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 21
“0001) with this OS benefit maintained only in the International Metastatic Renal Cell Cancer Database Consortium intermediate- and poor-risk groups.(65) A doublet ICB approach has also been utilised in the first-line setting in mccRCC, with a combination of NAVANI ET AL.”
MethodTivozanib in renal cell carcinoma: a new approach to previously treated disease
Salgia, N., Zengin, Z. B., & Pal, S. K. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920923818 · Cited by 21
Bersanelli, M., Brunelli, M., Gnetti, L., Maestroni, U. V., & Buti, S. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920915303 · Cited by 20
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
Schepisi, G., Conteduca, V., Casadei, C., Gurioli, G., Rossi, L., Gallá, V., Cursano, M. C., Brighi, N., Lolli, C., Menna, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.565857 · Cited by 20
“Nivolumab (10), nivolumab + ipilimumab (11), pembrolizumab in combination with axitinib (12), and avelumab plus axitinib (13) have demonstrated the most important advantages in RCC in terms of survival and response with respect to TKIs (12– 14).”
Backgroundhttps://cdrjournal.com/article/view/3531
Moreira, M., Pobel, C., Epaillard, N., Simonaggio, A., Oudard, S. M., & Vano, Y. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.16 · Cited by 39
Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma
Matsui, Y. (2020) · Cancers · doi:10.3390/cancers12102875 · Cited by 21
“Another first-line combination option is ICI+TKI, but the pivotal trials, such as KEYNOTE-426 and JAVELIN Renal 101, also excluded those with active CNS metastases [13,14].”
BackgroundYin, X., Zhang, X., Liu, Z., Sun, G., Zhu, X., Zhang, H., Zhu, S., Zhao, J., Chen, J., Shen, P., et al. (2020) · PubMed Central · Cited by 23
Economides, M. P., Shah, A. Y., Jiménez, C., Habra, M. A., Desai, M. D., & Campbell, M. T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.594264 · Cited by 20
“Combination of TKI and Immune Checkpoint Therapy in Other Malignancies In metastatic renal cell carcinoma (mRCC), the combination of axitinib (targeting VEGFR 1,2,3) with both pembrolizumab (KEYNOTE 426 study) and avelumab (JAVELIN 101 study) have both received FDA approval based on pivotal phase III trials (32, 33).”
BackgroundDumond, A., Brachet, E., Durivault, J., Vial, V., Puszko, A. K., Lepelletier, Y., Montemagno, C., Pagnuzzi‐Boncompagni, M., Hermine, O., Garbay, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01832-x · Cited by 20
Laccetti, A. L., Garmezy, B., Xiao, L., Economides, M. P., Venkatesan, A. M., Gao, J., Jonasch, E. W., Corn, P. G., Zurita‐Saavedra, A., Brown, L. C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3812 · Cited by 20
“nivolumab– pazopanib (N+P; 13), nivolumab– axitinib (6), nivolumab– lenvatinib (2),”
Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy
Kuusk, T., Abu‐Ghanem, Y., Mumtaz, F., Powles, T. B., & Bex, A. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000868 · Cited by 21
Self-citationMuramatsu-Maekawa, Y., Kawakami, K., Fujita, Y., Takai, M., Kato, D., Nakane, K., Kato, T., Tsuchiya, T., Koie, T., Miura, Y., et al. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20256 · Cited by 20
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news
Zambrana, F. R., Carril-Ajuria, L., de Liaño, A. G., Chanzá, N. M., Kopp, R. M., Castellano, D., & de Velasco, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102239 · Cited by 21
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
Cattrini, C., Messina, C. G. M., Airoldi, C., Buti, S., Roviello, G., Mennitto, A., Caffo, O., Gennari, A., & Bersanelli, M. (2021) · Therapeutic Advances in Urology · doi:10.1177/17562872211053189 · Cited by 21
“Exclusion criteria were (1) unavailable data about the outcomes of interest, (2) early phase studies (phase I/II), (3) non-randomized studies, (4) non-first-line therapy, and (5) exclusive nonclear cell histology.”
BackgroundPharmacometabolomics Applied to Personalized Medicine in Urological Cancers
Amaro, F., Carvalho, M. C., Bastos, M. D. L., de Pinho, P. G., & Pinto, J. (2022) · Pharmaceuticals · doi:10.3390/ph15030295 · Cited by 21
“More recently, the combination of these targeted drugs with immunotherapeutic agents (ipilimumab/nivolumab or pembrolizumab/axitinib) has been approved [53,54].”
BackgroundThe role of gut microbiome in immune modulation in metastatic renal cell carcinoma
Deluce, J. E., Vareki, S. M., & Fernandes, R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221122714 · Cited by 22
Cytoreductive nephrectomy in the current treatment algorithm
Kuusk, T., Szabados, B. E., Liu, W. K., Powles, T. B., & Bex, A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919879026 · Cited by 20
Self-citationLenvatinib plus Pembrolizumab for Renal Cell Carcinoma
Motzer, R., & Choueiri, T. K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107518 · Cited by 20
Du, Y., Mai, Y., Liu, Z., Lin, G., Luo, S., Guo, C., Qiao, G., Wang, L., Zhu, S., Zhou, Y., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500141 · Cited by 22
Salgia, N., Khan, A., Aubrecht, W. M., Twoey, G., Chow, J., Attwood, K. M., Yu, H., Chiello, J. L., Hansen, N. F., Wasik, B. J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.010 · Cited by 21
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 22
Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
Zhao, L., Ma, B., Yang, Y., Li, T., Han, L., & Gao, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00507 · Cited by 19
Roles of N6‐methyladenosine (m6A) RNA modifications in urological cancers
Wang, X., Xie, H., Ying, Y., Chen, D., & Li, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15750 · Cited by 21
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
Christensen, B. R., Hajja, Y., Koshkin, V. S., & Barata, P. C. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00814-z · Cited by 20
“, favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression [85].”
BackgroundImmune checkpoint blockade in renal cell carcinoma
Rappold, P. M., Silagy, A. W., Kotecha, R. R., & Hakimi, A. A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26339 · Cited by 23
“These encouraging results prompted KEYNOTE‐426 (NCT02853331), a landmark phase‐3 trial randomizing 1062 patients with treatment‐naïve metastatic RCC to pembrolizumab (200mg every 3 weeks) plus standard doses of axitinib or sunitinib.(40) The study met its primary endpoint demon-”
BackgroundInfluentialLiao, Z., Yao, H., Wei, J., Feng, Z., Chen, W., Luo, J., & Xu, C. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1348 · Cited by 19
“Recently, trail of KEYNOTE-426 and JAVELIN Renal 101 demonstrates using PD-1 immune checkpoint inhibitor-based combination regimens as the first line setting can significantly improve advanced RCC survival, which have been approved by FDA (7,8).”
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.